EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence

Wenqi Dong iD, Haiming Zhang iD, Shaowei Mu iD, Shuyi Shi iD, Junli Zhang iD, Keshu Xu iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70131 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Wenqi Dong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Incretins, Diabetes Mellitus, Type 2, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global prevalence and incidence of metabolic dysfunction‐associated fatty liver disease (MAFLD), including its progressive form metabolic dysfunction‐associated steatohepatitis (MASH), are steadily rising, making them the most common chronic liver diseases worldwide. However, therapeutic options for MAFLD are currently limited. Glucolipid dysregulation drives MAFLD pathogenesis through intertwined glucose metabolic imbalance and lipid accumulation. Patients with type 2 diabetes mellitus (T2DM) are particularly prone to developing MASH and are at a higher risk of progressing to cirrhosis and hepatocellular carcinoma. The coexistence of MAFLD and T2DM correlates with clinical prognosis and elevates the risk of extrahepatic complications. Given the close association between MAFLD and T2DM, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), which have been approved for the treatment of T2DM and obesity, were the first to be investigated in patients with MAFLD/MASH. Recently, beyond GLP‐1RAs, novel combination agents integrating glucose‐dependent insulinotropic peptide receptor (GIPR) and/or glucagon receptor (GCR) agonists have also been explored. A large number of phase II randomized clinical trials have demonstrated significant improvements in body weight, insulin resistance, and liver parameters. Thus, GLP‐1RAs and dual/triple agonists are promising for MAFLD/MASH, especially in those with obesity or T2DM. This study explores mechanisms and clinical evidence of incretin‐based therapies for MAFLD by targeting its core pathogenesis—glucolipid disorders. With growing evidence, it also forecasts the broad clinical prospects on MAFLD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsDiabetes Mellitus, Type 2Fatty LiverNon-alcoholic Fatty Liver DiseaseHumansGlucagon-Like Peptide-1 Receptor AgonistsAnimalsHypoglycemic Agents

Substanzen

IncretinsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Integrated Traditional Chinese and Western Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China.

ORCID-Profile: Wenqi Dong, Haiming Zhang, Shaowei Mu, Shuyi Shi, Junli Zhang, Keshu Xu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Dong, W., Zhang, H., Mu, S., Shi, S., Zhang, J., & Xu, K. (2026). Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70131

Vancouver

Dong W, Zhang H, Mu S, Shi S, Zhang J, Xu K. Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70131

BibTeX
@article{Dong2026,
  author = {Dong, Wenqi and Zhang, Haiming and Mu, Shaowei and Shi, Shuyi and Zhang, Junli and Xu, Keshu},
  title = {Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70131}
}
Kostenlos starten →